eptifibatide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 1040 188627-80-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • eptifibatide
  • eftifibatide
  • integrelin
  • integrilin
  • intrifiban
Cyclic peptide that acts as a platelet glycoprotein IIB-IIIA antagonist, reversibly inhibiting the binding of FIBRINOGEN; VON WILLEBRAND FACTOR; and other adhesive molecules to the GPIIB-IIIA RECEPTORS of platelets. It is used in the management of UNSTABLE ANGINA and in patients undergoing coronary ANGIOPLASTY and stenting procedures.
  • Molecular weight: 831.97
  • Formula: C35H49N11O9S2
  • CLOGP: -2.86
  • LIPINSKI: 3
  • HAC: 20
  • HDO: 11
  • TPSA: 323.89
  • ALOGS: -3.67
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 65 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.68 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.17 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 18, 1998 FDA SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Retroperitoneal haemorrhage 245.15 108.43 34 253 552 2357246
Thrombocytopenia 166.21 108.43 42 245 19089 2338709
Haemorrhage 108.99 108.43 27 260 11012 2346786

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 518.84 67.90 136 474 21113 1725058
Post procedural complication 187.57 67.90 40 570 2340 1743831
Haemorrhage intracranial 174.43 67.90 40 570 3270 1742901
Platelet count decreased 107.08 67.90 39 571 16484 1729687
Pulmonary alveolar haemorrhage 105.39 67.90 22 588 1143 1745028
Haemorrhage 101.84 67.90 33 577 9796 1736375
Hypotension 97.88 67.90 43 567 29611 1716560
Cardiogenic shock 84.03 67.90 21 589 2433 1743738
Post procedural haemorrhage 78.89 67.90 18 592 1412 1744759
Vascular pseudoaneurysm 76.64 67.90 14 596 357 1745814
Blood creatine phosphokinase MB increased 73.79 67.90 14 596 441 1745730
Pulmonary haemorrhage 70.61 67.90 17 593 1682 1744489
Gastrointestinal haemorrhage 68.06 67.90 27 583 14240 1731931

Pharmacologic Action:

SourceCodeDescription
ATC B01AC16 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
FDA PE N0000008832 Decreased Platelet Aggregation
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
CHEBI has role CHEBI:50427 platelet aggregation inhibitor
CHEBI has role CHEBI:50249 anticoagulant

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute coronary syndrome indication 394659003
Percutaneous coronary intervention indication 415070008
Acute hemorrhage contraindication 8573003
Blood coagulation disorder contraindication 64779008 DOID:1247
Impaired renal function disorder contraindication 197663003
Hemorrhagic cerebral infarction contraindication 230706003
Renal dialysis contraindication 265764009
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Surgical procedure contraindication 387713003
Hypertensive urgency contraindication 443482000
Acute Thromboembolic Stroke contraindication
Puncture of Noncompressible Artery contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.75 acidic
pKa2 12.86 acidic
pKa3 13.39 acidic
pKa4 13.57 acidic
pKa5 13.79 acidic
pKa6 9.79 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Integrin alpha-IIb/beta-3 Adhesion INHIBITOR IC50 6.24 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
D000077542 MESH_DESCRIPTOR_UI
4021114 VUID
N0000148569 NUI
C0253563 UMLSCUI
D06888 KEGG_DRUG
116065005 SNOMEDCT_US
4021114 VANDF
007557 NDDF
d04316 MMSL
4670 MMSL
75635 RXNORM
386998009 SNOMEDCT_US
213655 MMSL
CHEMBL1174 ChEMBL_ID
DB00063 DRUGBANK_ID
NA8320J834 UNII
7717 INN_ID
CHEBI:291902 CHEBI
448812 PUBCHEM_CID
6585 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Integrilin HUMAN PRESCRIPTION DRUG LABEL 1 0085-1136 INJECTION, SOLUTION 0.75 mg INTRAVENOUS NDA 17 sections
Integrilin HUMAN PRESCRIPTION DRUG LABEL 1 0085-1177 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 17 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 0338-9558 INJECTION 75 mg INTRAVENOUS ANDA 17 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 0338-9559 INJECTION 200 mg INTRAVENOUS ANDA 17 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 14335-070 INJECTION 2 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 14335-071 INJECTION 0.75 mg INTRAVENOUS ANDA 16 sections
EPTIFIBATIDE HUMAN PRESCRIPTION DRUG LABEL 1 16729-259 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 17 sections
EPTIFIBATIDE HUMAN PRESCRIPTION DRUG LABEL 1 16729-260 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 17 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 17478-902 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 17478-903 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 16 sections
eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 25021-408 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 16 sections
eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 25021-409 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 55150-218 INJECTION 75 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 55150-219 INJECTION 20 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 55150-220 INJECTION 200 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 62147-0600 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 62147-0601 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 62147-0602 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 63739-911 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 17 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 63739-923 INJECTION, SOLUTION 200 mg INTRAVENOUS ANDA 17 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 63739-970 INJECTION, SOLUTION 75 mg INTRAVENOUS ANDA 17 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 67457-629 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 67457-630 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 67457-631 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70121-1002 INJECTION 2 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70121-1003 INJECTION 0.75 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70436-026 INJECTION 2 mg INTRAVENOUS ANDA 16 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70436-027 INJECTION 0.75 mg INTRAVENOUS ANDA 16 sections